Allergies Clinical Trials Doctors FDA Approval 
The Pharma Data
JULY 29, 2021
BOTOX ® was first approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults. Patients treated for overactive bladder: In clinical trials, 36 of the 552 patients had to self-catheterize for urinary retention following treatment with BOTOX ® compared to 2 of the 542 treated with placebo.
XTalks
DECEMBER 20, 2023
And this year Eli Lilly stepped into the obesity drug market with its own GLP-1 weight loss drug Zepbound (tirzepatide), which the US Food and Drug Administration (FDA) approved in November of this year. There has been significant growth in the number of registered clinical trials globally, with a focus on interventional studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JUNE 18, 2021
BOTOX ® Cosmetic is the first and only product of its kind FDA-approved to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow’s feet in adults. Do not start any new medicines until you have told your doctor that you have received BOTOX ® Cosmetic in the past.
The Pharma Data
SEPTEMBER 10, 2021
About BOTOX ® BOTOX ® was first approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults. Adult Patients treated for overactive bladder due to neurologic disease: In clinical trials, 30.6% Tell your doctor if you have any breathing-related problems.
The Pharma Data
MARCH 30, 2021
Tell your doctor about all your muscle or nerve conditions such as ALS or Lou Gehrig’s disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX®.
The Pharma Data
SEPTEMBER 8, 2021
About BOTOX ® BOTOX ® was first approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults. Adult Patients treated for overactive bladder due to neurologic disease: In clinical trials, 30.6% Tell your doctor if you have any breathing-related problems.
The Pharma Data
NOVEMBER 4, 2020
“The third quarter was a productive but challenging quarter for Amarin as total net revenue grew to record levels reflecting increased prescription levels for VASCEPA, despite many patients not yet returning to their doctors’ offices for preventative healthcare due to the global pandemic,” stated John F. commercial team. “In
Expert insights. Personalized for you.
52 
Let's personalize your content